Skip to main content
Paediatrics & Child Health logoLink to Paediatrics & Child Health
. 2001 May-Jun;6(5):251–260.

Rare disease surveillance: An international perspective

Elizabeth J Elliott 1,2,, Angus Nicoll 3,4, Richard Lynn 4, Victor Marchessault 5, Remy Hirasing 6, Greta Ridley, on behalf of the secretariat and members of the International Network of Paediatric Surveillance Units2,*
PMCID: PMC2804555  PMID: 20084246

Abstract

BACKGROUND:

The International Network of Paediatric Surveillance Units (INoPSU) was established in 1998 and met formally for the first time in Ottawa, Ontario in June 2000.

OBJECTIVES:

To document the methodology and activities of existing national paediatric surveillance units; the formation of INoPSU; the diseases studied by INoPSU members; and the impact of such studies on education, public health and paediatric practice.

METHODS:

Directors of paediatric surveillance units in Australia, Britain, Canada, Germany, the Netherlands, Latvia, Malaysia, Papua New Guinea, New Zealand and Switzerland were asked to provide information on each unit’s affiliations, funding and staffing; the method of case ascertainment, the mailing list and response rates; and diseases studied. Original articles that reported data derived from units were identified by a search of an electronic database (MEDLINE), and additional information was obtained from units’ annual reports.

RESULTS:

Worldwide, 10 units (established from 1986 to 1997), use active national surveillance of more than 8500 clinicians each month to identify cases of rare or uncommon diseases in a childhood population (younger than 15 years of age) of over 47 million (monthly response rate 73% to 98%). By January 1999, units had initiated 147 studies on 103 different conditions, and 63 studies were completed.

CONCLUSION:

INoPSU enhances collaboration among units from four continents, providing a unique opportunity for simultaneous cross-sectional studies of rare diseases in populations with diverse geographical and ethnic characteristics. It facilitates the sharing of ideas regarding current methodology, ethics, the most appropriate means of evaluating units and their potential application.

Keywords: International network, Paediatrics, Rare diseases, Surveillance units

BACKGROUND

Rare disease surveillance

Rare and uncommon diseases number in the thousands, and contribute significantly to morbidity and mortality in childhood (1). Such diseases are demanding of health care resources, and have a large financial and emotional impact on families of affected children and communities. The low frequency of individual diseases may result in a delay in their recognition and diagnosis, increasing the risk of preventable complications or death. For many rare and uncommon conditions, little is known about their etiology, clinical spectrum, sequelae and management. However, to generate a sufficient number of cases to derive meaningful data, the study of rare and uncommon diseases requires data collection from large and, often, geographically diverse populations (1,2). In most countries, no mechanism has been available to enable the prospective collection of national epidemiological data on these diseases. Thus, management and resource decisions have relied on data contained in anecdotal or retrospective reports, often from a selected and potentially biased population.

In 1986, the British Paediatric Surveillance Unit (BPSU) was established to redress this deficiency (3). A joint initiative of the British Paediatric Association (now the Royal College of Paediatrics and Child Health), the Public Health Laboratory Service and the Institute of Child Health, the BPSU was based on a simple but novel concept. Each month, all paediatricians in Britain were sent a report card listing a number of rare conditions and were asked to indicate whether during that month they had seen any children who were newly diagnosed with any of the conditions listed. In 1992, Australia (2), the Netherlands (4) and Germany (5) established similar units. Malaysia followed in 1994; Switzerland (6), Canada (7), Papua New Guinea and Latvia in 1996; and New Zealand in 1997 (8). Units are currently being set up in Spain and the Republic of Ireland. In 1994 and 1998, Wales and the Republic of Ireland, respectively, established units that survey more common disorders on a regional basis. In Britain, subspecialty units conduct surveillance through the participation of gastroenterologists and opthalmologists using the methodology initially developed in Britain. The present paper represents the first collation of activities of paediatric surveillance units worldwide. MEDLINE was searched using Ovid and the terms ‘paediatric surveillance’ and ‘surveillance unit’, and additional details about publications were obtained from unit directors.

Establishment of an International Network of Paediatric Surveillance Units

European units have met informally since 1992 to discuss research protocols and funding issues. BPSU has had close ties with the Australian Paediatric Surveillance Unit (APSU) and the Canadian Paediatric Surveillance Program. The APSU advised units in Malaysia, Papua New Guinea and New Zealand during their development. The Australian and New Zealand units have representation on each other’s administrative committees, while Britain is represented on that of the Canadian unit. In 1996, units accepted the need for an International Network of Paediatric Surveillance Units (INoPSU) to formalize links among units. A proposal for INoPSU was ratified at the 22nd International Congress of Paediatrics held in Amsterdam, the Netherlands in August 1998.

The first INoPSU symposium, sponsored by Health Canada, was held in Ottawa, Canada in June 2000 in conjunction with Beyond 2000: Healthy Tomorrows for Children and Youth, a joint meeting of the Canadian Paediatric Society, the Canadian Institute of Child Health and the Canadian Academy of Child Psychiatry. INoPSU’s business meeting was attended by 12 representatives from eight countries. The increasingly important issues of privacy and confidentiality of health data were discussed, and INoPSU proposed a set of ethical guidelines for surveillance programs. A symposium on Methodological issues in paediatric surveillance included presentations on methodology, application and practical difficulties associated with surveillance, mother-child transmission of the human immunodeficiency virus (HIV), surveillance for perinatal exposure to HIV, Canada’s Immunization Monitoring Program ACTive and ethics. A keynote speaker gave the address Surveillance in children: Is there strength in numbers?

Mission and aims of INoPSU

The mission of INoPSU is “the advancement of knowledge about rare and uncommon childhood infections and disorders through the participation of paediatricians in surveillance on a national and international basis”. INoPSU’s primary aim is to facilitate communication and co-operation among national paediatric surveillance units (and researchers who use these units), and to assist in the development of new and existing units. INoPSU’s aims are detailed in Table 1. Communication is enhanced by the establishment of the INoPSU Web site <http//:www.inopsu.com> that links the Web sites of individual units and various national paediatric bodies to facilitate the sharing of information on methodology, evaluation and ethical issues, and data derived from studies. The simultaneous collection of identical data in different countries also allows comparisons to be made of disease incidence, management and outcome among geographic regions. INoPSU also aims to develop uniform diagnostic criteria, disseminate new knowledge and enhance the ability to mount international surveillance of emerging disorders rapidly.

TABLE 1:

Mission and aims of the International Network of Paediatric Surveillance Units

Mission
  The advancement of knowledge about uncommon childhood infections and disorders through the participation of paediatricians in surveillance on a national and international basis
Aims
  To encourage and facilitate
    communication and co-operation among existing units
    the development of new and existing units
    information sharing about the surveillance process and methods such as study selection, data validation, statistical techniques,
    surveillance methodology and evaluation, including development of an International Network of Paediatric Surveillance Units Web site
    peer review and evaluation of ethics and confidentiality issues
    simultaneous or sequential collection of comparable epidemiological and clinical data in two or more nations
    national comparisons of incidence estimates for selected rare disorders of childhood
    dissemination of information to national and international health authorities to raise awareness and encourage early diagnosis and management of rare conditions
    identification of emerging disorders
    establishment of international cohorts that could potentially support future research
    development and clarification of internationally recognized diagnostic criteria
    dissemination of new knowledge to the general public and others (eg, parent support groups)
    prompt response to international emergencies relating to emerging rare childhood conditions

INoPSU structure

Founding members of the INoPSU network are listed in Table 2. An elected secretariat oversees INoPSU, undertaking regular consultation with units and seeking funding, as necessary. An ‘international link person’ has been nominated from each unit. INoPSU functions primarily as an electronic network via its Web site. BPSU acts as the INoPSU secretariat, and APSU administers INoPSU’s Web site.

Table 2:

Founding members of the International Network of Paediatric Surveillance Units

Founding member Year established Affiliations Staffing (salaried FTE)
Australian Paediatric Surveillance Unit 1992 Division of Paediatrics, Royal Australasian College of Physicians 1.8
Centre for Disease Control, Department of Health & Aged Care
British Paediatric Surveillance Unit 1986 Scottish Centre for Infectious and Environmental Health 1.4
Faculty of Paediatrics, Royal College of Physicians (Ireland)
Public Health Laboratory Service
Royal College of Paediatrics and Child Health
Institute of Child Health
Canadian Paediatric Surveillance Program 1996 Canadian Paediatric Society 1.0
Centre for Infectious Disease Prevention and Control, Health Canada
German Paediatric Surveillance Unit 1992 German Paediatric Association 1.0
Latvian Paediatric Surveillance Unit 1996 Latvian Paediatric Association 1.0
Malaysian Paediatric Surveillance Unit 1993 Malaysian Paediatric Association 1.0
Netherlands Paediatric Surveillance Unit 1992 Dutch Paediatric Association 0.6
New Zealand Paediatric Surveillance Unit 1997 New Zealand Paediatric Society 0.5
New Zealand Ministry for Health
Papua New Guinea Paediatric Surveillance Unit 1996 Paediatric Society for Papua New Guinea 0
HOPE worldwide (Papua New Guinea branch)
Swiss Paediatric Surveillance Unit 1995 Swiss Federation of Public Health 0.3
Swiss Paediatric Society

FTE Full time equivalent

Most national units are affiliated with their country’s professional paediatric organization, and a variety of other organizations concerned with child and public health are frequently represented on the units’ administrative boards. Staffing levels vary (Table 2).

Conditions studied and selection of studies

Paediatric surveillance units provide a mechanism for active case finding for individuals or organizations wishing to study rare or uncommon conditions in childhood. Units encourage or facilitate studies but do not generally undertake research. Units simultaneously collect monthly data on eight or more conditions. Conditions studied include infections, infection-related conditions, vaccine-preventable diseases, congenital and inherited diseases, unusual injuries or therapies, and rare complications of common diseases. Current and completed studies and conditions approved for future study are shown in Tables 3 and 4; they indicate a considerable overlap among units. By the start of 1999, the 10 units had initiated 147 studies on 103 different conditions. At this time, 63 of these studies had been completed and a further 12 applications had been approved for new studies. Eight collaborative studies have been undertaken among units. Some studies also incorporate the collection of biological specimens from notified cases (Table 3).

Table 3:

Conditions currently under surveillance by national paediatric surveillance units and studies that requested biological specimens at January 1999

Condition Unit performing surveillance
Current studies Specimens requested
Acute flaccid paralysis APSU, CPSP, NSCK, NZPSU, PNGPSU, SPSU APSU, CPSP, NZPSU, PNGPSU, SPSU
Aseptic meningitis following measles, mumps, rubella vaccine ESPED
Chronic inflammatory bowel disease* BPSU
Celiac disease LPSU, NSCK LPSU
Congenital adrenal hyperplasia NSCK
Congenital brachial palsy BPSU
Congenital heart disease MPSU
Congenital hypothyroidism PNGPSU
Congenital rubella APSU, BPSU, CPSP, NZPSU, SPSU CPSP, SPSU
Cystic fibrosis LPSU
Duchenne muscular dystrophy MPSU
Encephalitis in children three to 36 months of age BPSU BPSU
Fatal or near fatal asthma MPSU
Group B streptoccal infection NSCK
Hemolytic uremic syndrome APSU, BPSU, ESPED, NZPSU, SPSU APSU, BPSU, NZPSU
Vitamin K deficiency bleeding (including hemorrhagic disease of the newborn) APSU, CPSP, ESPED, NZPSU, SPSU CPSP, SPSU
Hirschsprung disease APSU
HIV/AIDS with or without perinatal exposure to HIV APSU, BPSU, LPSU, MPSU, NSCK, NZPSU, PNGPSU BPSU, LPSU
Hospitalized pertussis ESPED, NSCK
Idiopathic thrombocytopenia ESPED
Insulin-dependent diabetes mellitus ESPED, LPSU, NSCK, PNGPSU, NZPSU LPSU
Invasive Haemophilus influenzae infection APSU, BPSU, ESPED APSU, BPSU
Ischemic stroke in infants ESPED
Leukemia LPSU LPSU
Lues congenita LPSU LPSU
Multiple sclerosis in infants ESPED
Neonatal fungal septicemia ESPED
Neonatal herpes simplex virus infection APSU, NZPSU
Neonatal meningitis MPSU
Neural tube defects NSCK
Neurological endemic cretinism PNGPSU
Organocidopathia and fatty acid oxidation defects ESPED
Paediatric malignancies PNGPSU
Pneumoccoccal sepsis and/or meningitis ESPED ESPED
Prader-Willi syndrome APSU
Primary immunodeficiency disorders§ APSU
Progredient subacute neurological diseases LPSU LPSU
Progressive intellectual and neurological deterioration (including Creutzfeld-Jakob disease) BPSU, CPSP CPSP
Renal tubular acidosis PNGPSU
Retinopathy of prematurity (stage III and beyond) NZPSU
Reye syndrome BPSU
Rotavirus infection NSCK
Severe combined immunodeficiency APSU
Subacute sclerosing panencephalitis APSU, BPSU, CPSP, PNGPSU CPSP, PNGPSU
Subdural hematoma or effusion (in children younger than two years of age) BPSU, NZPSU
Transient myeloproliferative syndrome in newborns with Down syndrome ESPED
Venous thromboembolic complaints NSCK
*

Ulcerative colitis, Crohn’s disease and intermediate colitis;

Previously studied by the British Paediatric Surveillance Unit (BPSU) from 1986 to 1989;

Wilms tumour, Burkitt lymphoma, leukemia, neuroblastoma, lymphoma (non-Burkitt), other;

§

Predominantly antibody defects (eg, X-linked agammaglobulinemia, immunogloblulin A deficiency, immunogloblulin G subclass deficiency), combined immunodeficiencies (eg, severe combined immunodeficiency, common variable immunodeficiency), immunodeficiencies with other major defects (eg, Wiscott-Aldrich syndrome, Di George syndrome, ataxia telangiectasia), complement deficiencies, including C1 esterase inhibitor deficiency (eg, hereditary angioneurotic edema), defects of phagocytic function (eg, chronic granulomatous disease, leukocyte-adhesion deficiency, Schwachman syndrome) and other. AIDS Acquired immunodeficiency syndrome; APSU Australian Paediatric Surveillance Unit; CPSP Canadian Paediatric Surveillance Program; ESPED Erhebungseinheit fur Seltene Padiatrische Erkrankungen in Deutschland; HIV Human immunodeficiency virus; LPSU Latvian Paediatric Surveillance Unit; MPSU Malaysian Paediatric Surveillance Unit; NSCK Nederlands Signalerings-Centrum Kindergeneeskunde; NZPSU New Zealand Paediatric Surveillance Unit; PNGPSU Papua New Guinea Paediatric Surveillance Unit; SPSU Swiss Paediatric Surveillance Unit

Table 4:

Conditions for which studies were completed by national paediatric surveillance units at January 1999, and approvals for future studies

Condition Unit performing surveillance
Completed studies Approved studies
Acute flaccid paralysis BPSU
Acute liver failure MPSU
AIDS in childhood BPSU
Anaphylaxis CPSP
Androgen insensitivity syndrome BPSU
Autoimmune hepatitis ESPED
Arthrogryposis multiplex congenita APSU
Cerebral edema in diabetic ketoacidosis CPSP
CHARGE association APSU
Chemistry set poisoning BPSU
Childhood dementia APSU
Congenital adrenal hyperplasia APSU
Congenital cytomegalovirus infection APSU
Congenital cataracts BPSU
Congenital dislocation of the hip BPSU
Congenital and neonatal varicella APSU
Congenital rubella NSCK
Congenital syphilis BPSU
Congenital toxoplasmosis BPSU, SPSU
Cystic periventricular leukomalacia SPSU
Drowning or near-drowning APSU, BPSU
Extrahepatic biliary atresia APSU, BPSU
Fatal or near fatal asthma ESPED
Galactosemia BPSU
Group B streptoccal infection CPSP
Hemophagocytic lymphohistiocytosis BPSU
Hemolytic uremic syndrome BPSU (study recommenced in 1997) SPSU
Hemorrhagic disease of the newborn (includes vitamin K deficiency bleeding) NSCK BPSU
Herpes 6/7 virus infection BPSU
High order births BPSU
Hemorrhagic shock encephalopathy syndrome BPSU, ESPED
Idiopathic interstitial lung disease CPSP
Idiopathic thrombocytopenia ESPED
Insulin-dependent diabetes mellitus BPSU
Invasive Haemophilus influenzae infection ESPED, NSCK APSU
Irregular blood group reactions (non-D, non-ABO) NSCK
Juvenile dermatomyositis BPSU
Kawasaki disease APSU, BPSU, ESPED LPSU, MPSU
Long term total parenteral nutrition BPSU
Lowe syndrome BPSU
Medium chain acyl CoA dehydrogenase deficiency BPSU
Measles-mumps-rubella vaccine-associated meningoencephilitis BPSU
Munchausen syndrome by proxy and/or nonaccidental poisoning and suffocation BPSU APSU
Nephrotic syndrome (congenital and idiopathic) APSU
Neonatal thrombosis ESPED
Neonatal meningitis BPSU
Neonatal necrotising enterocolitis BPSU
Neural tube defects CPSP
Ondine’s curse ESPED
Perinatal hemocromatosis CPSP
Postneonatal mortality in premature babies NSCK
Pyridoxine-dependent status epilepticus BPSU CPSP
Rett syndrome APSU, BPSU Repeat study APSU
Reye syndrome ESPED
Rheumatic fever BPSU, NSCK
Rickets CPSP
Sickle cell disease NSCK
Thalassemia major NSCK, PNGPSU
Tic-borne encephalitis ESPED
Transient and permanent neonatal diabetes mellitus BPSU
Visual impairment and blindness BPSU
Water births BPSU
X-linked anhydrotic ectodermal dysplasia BPSU

AIDS Acquired immunodeficiency syndrome; APSU Australian Paediatric Surveillance Unit; BPSU British Paediatric Surveillance Unit; CHARGE Coloboma, heart defects, atresia choanae, retardation of growth and development and/or central nervous system anomalies, genital anomalies and/or hypogonadism, and ear anomalies and/or hearing loss; CPSP Canadian Paediatric Surveillance Program; ESPED Erhebungseinheit fur Seltene Padiatrische Erkrankungen in Deutschland; LPSU Latvian Paediatric Surveillance Unit; MPSU Malaysian Paediatric Surveillance Unit; NSCK Nederlands Signalerings-Centrum Kindergeneeskunde; NZPSU New Zealand Paediatric Surveillance Unit; PNGPSU Papua New Guinea Paediatric Surveillance Unit; SPSU Swiss Paediatric Surveillance Unit

Applications to conduct a study are considered by a scientific panel with epidemiological and public health expertise, and may also be reviewed externally by experts in the field. To be approved for study, conditions must fulfill certain criteria. They must be sufficiently uncommon so that they do not overload the system, although short-duration studies of relatively common conditions may be studied. Research questions must be important and, ideally, all patients should be seen by clinicians whose names are on the mailing list. Similar data should not be readily available through an existing source, although when alternative sources are available, their use is encouraged, particularly when the study aims require complete or near complete case ascertainment. Studies must conform to international ethical guidelines (International Ethical Guidelines for Biomedical Research Involving Human Subjects [9] prepared by the Council for International Organizations of Medical Sciences and the World Health Organization in 1993).

Studies judged to be feasible and to have sufficient resources are monitored for one to three years initially. Studies may be extended if the condition is of particular public health significance (eg, HIV and AIDS) or the paediatric surveillance unit is the optimal mechanism for gathering routine surveillance data. A protocol sheet outlining study aims, case definition and reporting instructions is distributed to the mailing list before the commencement of a new study.

METHODS

Data collection

According to the principle of ‘active’ surveillance, initiation for notification comes from the unit rather than the clinician. Active surveillance results in considerably higher case ascertainment than passive surveillance, and minimizes recall bias (2). The methodology varies slightly among units to suit local conditions. In principle, the surveillance unit sends a monthly report card to a ‘mailing list’ of paediatricians and asks paediatricians simply to indicate whether they have ‘nothing to report’, or to mark the number of new cases of each condition listed that they saw during the previous month. Cards are returned to the unit. The individual or organization responsible for a study (the ‘investigator’) is notified about positive case reports and given the contact details for the reporting clinician. The investigator is then responsible for obtaining clinical and epidemiological data from reporting doctors by postal questionnaire, and for the collation, analysis, presentation and publication of data and feedback to the unit’s secretariat. Alternative data sources may be used to validate ascertainment. In most countries, data collection is anonymous; investigators use a patient code and have no direct access to information that would allow them to identify or contact patients, or their families (Table 5).

Table 5:

Reporting mechanisms used by member countries of the International Network of Paediatric Surveillance Units

Country Reply-paid cards Report cards (% returned) Other forms of reporting (conditions reported) Questionnaire (% returned)
Australia Yes 93 Telephone (AFP) 66 to 97
E-mail (all conditions)
Britain No 94 Telephone (AFP, IILH, Hib, HUS, encephalitis) 85 to 98
Canada Yes 86 None 90 to 100
Germany No 95 None 47 to 100
Latvia No Not known Telephone (all conditions) Not known
E-mail (all conditions)
Malaysia Yes 75 None Not known
Netherlands Yes 92 Telephone (Pertussis) 93
New Zealand Yes 94 Telephone (AFP, HUS) Not known
Fax (AFP, HUS)
E-mail (AFP/HUS)
Papua New Guinea Yes 72.7 None Not known
Switzerland Yes 98 None 96 to 100
*

129 (14%) of 928 clinicians reported to the Australian Paediatric Surveillance Unit by e-mail in 1998, and over 30% used e-mail reporting in 1999. AFP Acute flaccid paralysis; IILH Idiopathic interstitial lung disease; Hib Haemophilus influenzae type b; HUS Hemolytic uremic syndrome

Some units use a reply-paid report card, and e-mail reporting was introduced in Australia in 1997 (Table 5). Telephone and facsimile reporting is requested for some studies when a timely report is required (eg, to facilitate obtaining biological specimens). On receipt of a case notification, two units (the Canadian Paediatric Surveillance Program and the New Zealand Paediatric Surveillance Unit) send study questionnaires directly to the notifying clinician rather than sending the notifying doctor’s details to the investigator in an attempt to make the receipt of questionnaires more timely (8). In 1998, the return rate of monthly cards to units ranged from 73% to 98%, and that of questionnaires ranged from 47% to 100% (Table 5). The proportion of clinicians who report by e-mail to APSU increased from 14% in 1997 to over 30% in 1999, with a 99% response rate (Table 5). The workload for most clinicians who participate in national surveillance of rare diseases is low. In any single year, a large proportion of clinicians on mailing lists do not report a single case and, hence, are not required to complete a questionnaire requesting further details (10,11).

Mailing lists

In 1998, mailing lists ranged in size from seven to 2125 individuals (Table 6), and included general and specialist paediatricians and nonpaediatric specialists (eg, paediatric surgeons and dermatologists). In Switzerland, Germany and Latvia, department heads rather than individual clinicians report on behalf of their colleagues. Surveillance covers the national population younger than 15 years of age, which ranges from 0.5 million individuals in Latvia to approximately 13 million patients in the British Isles (Table 6). Currently, over 8500 paediatricians worldwide contribute monthly to the reporting of uncommon diseases in a population of over 47.6 million.

Table 6:

Mailing lists used by member countries of the International Network of Paediatric Surveillance Units

Country Population younger than 15 years of age (millions) Number of clinicians on mailing list
Australia 2 928
Britain 12.8 1925
Canada 6 2125
Germany 12 496*
Latvia 0.5 7*
Malaysia 7.6 340
Netherlands 2.8 416
New Zealand 0.8 163
Papua New Guinea 1.8 40
Switzerland 1.3 41
*

Reporting by heads of hospital paediatric units;

Reporting by heads of paediatric centres on behalf of 500 respondents

Funding sources

Units represent ‘value for money’ because they conduct up to 15 research studies simultaneously; however, fixed costs include postage and salaries. Most units are funded by a variety of government, charitable and commercial sources. The national health department is the predominant funding source in New Zealand, Switzerland and Britain, and a major funder in Australia and Canada. In some countries, an investigator fee contributes towards infrastructure costs and ranges from EURO€111 to EURO€5555 per year.

RESULTS

Evaluation

The Australian unit has undergone formal evaluation (12), and some of its findings are applicable to other units. The evaluation showed that clinicians perceived this method of surveillance to be simple and useful. The high return rate of monthly cards and questionnaires indicates acceptability by clinicians on the mailing list. The sensitivity of case ascertainment was acceptable for most APSU studies, and the positive predictive value was over 70% for most notifications.

Although desirable, full case ascertainment is not always achieved (1,1214). Indeed, complete case ascertainment is not always required to fulfill the aims of some studies, especially when the system aims to identify cohorts that are later invited to enter randomized control trials or clinical surveys. However, it is important that mailing lists are as inclusive (hence as representative) as possible, to maximize ascertainment. A comparison of the BPSU mailing list with the 1996 national paediatric manpower census identified the involvement of 96% of all paediatricians who are most likely to see cases (15). Where full ascertainment is desired, alternative sources of data are used to supplement surveillance unit data. These sources include birth defect registers, death registers, parent support groups and laboratory surveillance programs (1,16). When used in conjunction with other data sources, this methodology results in levels of case ascertainment between 70% and 95% (15,1719).

The APSU evaluation concluded that the support of professional paediatric bodies, the simplicity of the reporting scheme, the low workload for clinicians, and the educational value and relevance for clinical practice accounted for the high compliance within these schemes (12).

Impact

The effectiveness of units is measured by their impact on education and public health. Educational impact is achieved by the dissemination of information via newsletters, annual reports, presentations to scientific meetings and publication in the scientific literature. In the APSU evaluation, the majority of clinicians reported that the provision of diagnostic criteria and information derived from studies was educationally useful, and 33% of respondents reported said that such information had informed or changed their clinical practice (12). The increase in reports of Kawasaki disease in the British Isles during 1986/87 was attributed not to a true increase in incidence but to the newly established active reporting system of the BPSU, which increased clinicians’ awareness of the diagnostic criteria for this condition (20). A similar phenomenon occurred in Australia when congenital and neonatal varicella became notifiable to the APSU (21).

Many units have affected public health by monitoring outcomes of national vaccination programs, the late sequelae of vaccination or the incidence of vaccine-preventable conditions before the availability of vaccination. These monitoring effects include surveys of congenital rubella (21,22), subacute sclerosing panencephalitis (23), meningoencephalitis after measles-mumps-rubella vaccination (24), acute flaccid paralysis (25,26) and Haemophilus influenzae type b vaccine failures (14,27), with the latter being a part of a collaborative Dutch and British surveillance.

Units also have the ability to respond rapidly to public health emergencies. Several units have assessed the impact of changing the route of administration of vitamin K prophylaxis on the incidence of vitamin K deficiency bleeding in the newborn (2833). Other units are monitoring the association between hemolytic uremic syndrome and Shiga toxin-producing Escherichia coli (34,35). The recent identification of new variant Creutzfeld-Jakob disease in Britain (36) has led to the monitoring of the incidence and etiology of progressive intellectual and neurological degeneration in childhood (37). Studies have also provided information that has influenced public health policy development as follows.

Studies of HIV/AIDS and perinatal exposure to HIV provided information on perinatal transmission of HIV (38), and the role of screening and treatment in pregnancy (17,39).

Studies on toxoplasmosis and neonatal herpes simplex virus infection concluded that universal screening in pregnancy was not warranted due to insufficient case frequency (40,41).

Repeated warnings about the danger of using acetylsalicylic acid in childhood were issued after the BPSU study on Reye syndrome described the continued association between acetylsalicylic acid use in children and this disorder (42,43).

The APSU study on hemolytic uremic syndrome provided data to the National Food Authority to support a change in the Food Standards Code relating to the safety of fermented meat small goods products (34,44).

Studies allowed the evaluation of prevention strategies such as pool fencing (45).

Studies identified potential risk factors, for example epilepsy for drowning (45), or being the child of an immigrant parent not vaccinated for congenital rubella (46).

The BPSU study on chemistry set poisoning supported data that led to changes in European Union law regarding the packaging of children’s toys (47).

Some studies, for example, on Rett Syndrome (4850), provided insight into disease etiology and identified cohorts for future research, including randomized clinical trials of treatment (51). Studies also provided information on current management strategies, such as the use of immunoglobulin in Kawasaki disease (20,52), and the usefulness of a pilot neonatal screening program for congenital adrenal hyperplasia (53). Data from studies also allowed the validation of diagnostic criteria (52), documentation of short term outcomes (26,45) and the description of the clinical spectrum of disease (54). Dutch, British and German units collaborated on surveillance of insulin-dependent diabetes mellitus in children younger than five years of age (18), while Dutch and British units collaborated on a study on H influenzae type b vaccine failures (27). The use of several Australian study protocols (hemolytic uremic syndrome, congenital rubella, acute flaccid paralysis, HIV/AIDS, neonatal herpes simplex virus infection and vitamin K deficiency bleeding) by New Zealand researchers will allow international comparison of data. The exciting potential for the simultaneous study of a single condition by all INoPSU member countries also exists.

CONCLUSIONS

In formalizing established links among 10 existing national paediatric surveillance units, INoPSU provides a unique mechanism for the development of international collaborations. INoPSU allows the collection of information from member nations with diverse geographical locations and population characteristics, the development of uniform diagnostic criteria and the dissemination of new knowledge that will benefit paediatric care. A crucial role of INoPSU will be to ensure the ongoing evaluation of the methodology used by units and the quality of data collected.

Acknowledgments

INoPSU particularly acknowledges all paediatricians and other specialists who contribute worldwide to the surveillance of childhood disease by reporting through paediatric surveillance units, and the major sponsors of national paediatric surveillance units. The authors thank Ms Gabrielle Williams for her contribution to the preparation of the manuscript.

Footnotes

Internet addresses are current at the time of publication.

REFERENCES

  • 1.Hall SM, Nicoll A. The British Paediatric Surveillance Unit: A pioneering method for investigating the less common disorders of childhood. Report of a seminar held in June 1995. Child Care Health Dev. 1998;24:129–43. doi: 10.1046/j.1365-2214.1998.00052.x. [DOI] [PubMed] [Google Scholar]
  • 2.Elliott EJ, Chant KG. Rare disease surveillance. J Paediatr Child Health. 1994;30:463–5. doi: 10.1111/j.1440-1754.1994.tb00711.x. [DOI] [PubMed] [Google Scholar]
  • 3.Hall SM, Glickman M. The British Paediatric Surveillance Unit. Arch Dis Child. 1988;63:344–6. doi: 10.1136/adc.63.3.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Schmidt E, von Kries R, Herzig P. Die Erhebungseinheit fur seltene padiatrische Erkrankungen in Deutschland (ESPED). Teil 1: Angebot eines Instrumentes fur epidemiologische Forschung. Monatschr Kinderheilk. 1993;141:758–9. [Google Scholar]
  • 5.Schmidt E, von Kries R, Herzig P. Die Erhebungseinheit fur seltene padiatrische Erkrankungen in Deutschland (ESPED). Teil 2: Empfehlungen fur die Bewerbung um Aufnahme von Studien. Monatschr Kinderheilk. 1993;141:970–1. [Google Scholar]
  • 6.Zimmerman H, Desgrandchamps D, Schubiger G. The Swiss Paediatric Surveillance Unit (SPSU) Soz Praventivmed. 1995;40:392–5. doi: 10.1007/BF01325425. [DOI] [PubMed] [Google Scholar]
  • 7.Sockett PN. The Canadian Paediatric Surveillance Program: Two years of a system for investigating unusual paediatric disorders. Paediatr Child Health. 1998;3:240–5. doi: 10.1093/pch/3.4.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dow N, Dickson N, Taylor B, Darlow B, Wong W, Lennon D. The New Zealand Paediatric Surveillance Unit: establishment and first year of operation. N Z Public Health Rep. 1999;6:41–4. [Google Scholar]
  • 9.International Ethical Guidelines for Biomedical Research Involving Human Subjects Geneva: Council for International Organizations of Medical Sciences; 1993. <http://www.codex.uu.se/texts/international.html> (Version current at April 3, 2001) [PubMed] [Google Scholar]
  • 10.Williams K, Elliott E. Role of the Australian Paediatric Surveillance Unit in monitoring communicable diseases of chilhood. Commun Dis Intell. 1998;22:283–7. [PubMed] [Google Scholar]
  • 11.Lynn R, Hall SM. The British Paediatric Surveillance Unit: Activities and developments in 1990 and 1991. Commun Dis Rep Rev. 1992;2:R145–8. [PubMed] [Google Scholar]
  • 12.Gazarian M, Williams K, Elliott E, et al. Evaluation of a national surveillance unit. Arch Dis Child. 1998;80:21–7. doi: 10.1136/adc.80.1.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wadsworth EJK, Sheild JPH, Hirasing RA, et al. Diabetes incidence and ascertainment in children under 5 years for the UK, the Netherlands and Germany. Pediatr Res. 1995;38:423–33. [Google Scholar]
  • 14.Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet. 1997;349:1197–202. doi: 10.1016/s0140-6736(96)06392-1. [DOI] [PubMed] [Google Scholar]
  • 15.Lynn R, Nicoll A, Guy M. British Paediatric Surveillance Unit 11th Annual Report. London: British Paediatric Surveillance Unit; 1997. 1998. [Google Scholar]
  • 16.Godward S, Dezateux C. Validation of the reporting bases of the orthopaedic and paediatric surveillance schemes. Arch Dis Child. 1996;75:232–6. doi: 10.1136/adc.75.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ades AE, Davison CF, Holland FJ, et al. Vertically transmitted HIV infection in the British Isles. BMJ. 1993;306:1296–9. doi: 10.1136/bmj.306.6888.1296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wadsworth E, Shield J, Hunt L, Baum D. Insulin dependent diabetes in children under 5: Incidence and ascertainment validation for 1992. BMJ. 1995;310:700–3. doi: 10.1136/bmj.310.6981.700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rahi JS, Dezateux C. Capture-recapture analysis of ascertainment by active surveillance in the British Congenital Cataract Study. Invest Ophthalmol Vis Sci. 1999;40:236–9. [PubMed] [Google Scholar]
  • 20.Dhillon R, Newton L, Rudd P, Hall SM. Management of Kawasaki disease in the British Isles. Arch Dis Child. 1993;69:631–8. doi: 10.1136/adc.69.6.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Forrest JM, Burgess MA. Plotting the demise of congenital rubella and varicella. Aust NZ J Public Health. 1996;20:4–6. doi: 10.1111/j.1467-842x.1996.tb01322.x. [DOI] [PubMed] [Google Scholar]
  • 22.Miller E, Waigh PA. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: 4th joint report from the PHLS and The National Congenital Rubella Surveillance Programme. Commun Dis Rep Rev. 1997;7:26–32. [PubMed] [Google Scholar]
  • 23.Miller C, Farrington CP, Harbart K. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1970–1989. Int J Epidemiol. 1993;21:998–1006. doi: 10.1093/ije/21.5.998. [DOI] [PubMed] [Google Scholar]
  • 24.Miller E, Goldacre M, Pugh S, et al. Risk of meningitis after measles, mumps and rubella vaccine in UK children. Lancet. 1993;341:979–82. doi: 10.1016/0140-6736(93)91069-x. [DOI] [PubMed] [Google Scholar]
  • 25.Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985–91. BMJ. 1992;305:79–82. doi: 10.1136/bmj.305.6845.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.D’Souza RM, Kennett M, Antony J, et al. Surveillance of acute flaccid paralysis in Australia, 1995–97. Australian Paediatric Surveillance Unit. J Paediatr Child Health. 1999;35:536–40. doi: 10.1046/j.1440-1754.1999.00413.x. [DOI] [PubMed] [Google Scholar]
  • 27.Conyn-van-spendonck MAE, Heath P, Slack M, von Kries R. Paediatric surveillance as a tool for the evaluation of national immunisation programmes, particularly of immunisation against invasive infection by Haemophilus influenzae type b. Pediatr Res. 1995;38:23–33. [Google Scholar]
  • 28.Cornelissen M, McNinch A, Tripp J, Shrubiger G, Loughnan P, von Kries R. Prospective studies on vitamin K deficiency bleeding in various countries. Eur J Pediatr. 1997;156:126–30. doi: 10.1007/s004310050570. [DOI] [PubMed] [Google Scholar]
  • 29.Cornelissen M, Von Kries R, Loughnan P, Schubiger G. Prevention of vitamin K deficiency bleeding: Efficacy of different multiple oral dose schedules of vitamin K. Eur J Pediatr. 1997;156:126–30. doi: 10.1007/s004310050570. [DOI] [PubMed] [Google Scholar]
  • 30.Bundesamt fur Gesundheit/Office federal de la sante publique. Schebiger G, Stocker Ch, Banziger O, Zimmerman H. Mischmizellen-vitamin K, SPSU-Jahresgericht 1995/SPSU – Rapport annuel. Bull BAG/OFSP. 1996;29:8–11. [Google Scholar]
  • 31.Von Kries R, Hachmeister A, Gobel U. Repeated oral vitamin K prophylaxis in West Germany: Acceptance and efficacy. BMJ. 1995;310:1097–8. doi: 10.1136/bmj.310.6987.1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.McNinch AW, Tripp J. Haemorrhagic disease of the newborn in the British Isles: A two year prospective study. BMJ. 1991;303:1105–9. doi: 10.1136/bmj.303.6810.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.McMillan DD, Wu J. Approach to the bleeding newborn. Paediatr Child Health. 1998;3:399–401. doi: 10.1093/pch/3.6.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Elliott E, Henning P, Hogg G, et al. Haemolytic uraemic syndrome in Australia 1994–5. Commun Dis Intell. 1995;19:310–2. [Google Scholar]
  • 35.Milford DV, Taylor CM, Gutteridge B, Hall SM, Rowe B, Kleanthous H. Haemolytic uraemic syndromes in the British Isles 1985–8: Association with verotoxin producing Escherichia coli. Part 1:clinical and epidemiological aspects. Arch Dis Child. 1990;65:716–21. doi: 10.1136/adc.65.7.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Will RG, Ironside JW, Zeidler M, et al. A new variant of CJD in the UK. Lancet. 1996;347:921–5. doi: 10.1016/s0140-6736(96)91412-9. [DOI] [PubMed] [Google Scholar]
  • 37.Guy M, Lynn R, Nicoll A.British Paediatric Surveillance Unit 10th Annual Report 1995/1996London: British Paediatric Surveillance Unit; 1996 [Google Scholar]
  • 38.McDonald AM, Cruickshank M, Zeigler JB, Elliot EJ, Kaldor JM. Perinatal exposure to HIV in Australia, 1982–1994. Med J Aust. 1997;166:77–80. doi: 10.5694/j.1326-5377.1997.tb138725.x. [DOI] [PubMed] [Google Scholar]
  • 39.Macdonagh SE, Masters JM, Helps BA, Tookey PA, Ades AE, Gibb DM. Antenatal HIV testing in London: Policy, uptake and detection. BMJ. 1996;12:532–3. doi: 10.1136/bmj.313.7056.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Peckham C, Logan S. Screening for toxoplasmosis during pregnancy. Arch Dis Child. 1993;68:3–5. doi: 10.1136/adc.68.1_spec_no.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Tookey PA, Peckham CS. Neonatal herpes simplex virus infection in the British Isles. Paediatr Perinat Epidemiol. 1997;10:432–42. doi: 10.1111/j.1365-3016.1996.tb00070.x. [DOI] [PubMed] [Google Scholar]
  • 42.Newton L, Hall SM. Reye’s syndrome in the British Isles: Report for 1990/91 and the first decade of surveillance. Commun Dis Rep Rev. 1993;3:R11–6. [PubMed] [Google Scholar]
  • 43.Hall S, Lynn R. Reye’s syndrome. N Engl J Med. 1999;341:845–6. doi: 10.1056/NEJM199909093411112. [DOI] [PubMed] [Google Scholar]
  • 44.Robins-Browne R, Elliot E, Desmarchelier P. Shiga toxin-producing Escherichia coli in Australia. In: Kaper JB, O’Brien AD, editors. Escherichia coli 0157:H7 and other Shiga toxin-producing E coli strains. Washington: American Society for Microbiology; 1998. pp. 66–72. [Google Scholar]
  • 45.Kemp AM, Sibert JR. Drowning and near drowning in children in the United Kingdom: Lessons for prevention. BMJ. 1992;67:985–93. doi: 10.1136/bmj.304.6835.1143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Burgess MA, Forrest JM. Congenital rubella in Australia 1993 and early reports for 1994. Commun Dis Intell. 1995;19:234–8. [PubMed] [Google Scholar]
  • 47.Mucklow ES. Chemistry set poisoning. Int J Clin Pract. 1997;51:321–3. [PubMed] [Google Scholar]
  • 48.Leonard H, Thomson M, Bower C, Fyfe S, Constantinou J. Skeletal abnormalities in Rett syndrome: Increasing evidence for dysmorphogenetic defects. Am J Med Genet. 1995;58:282–5. doi: 10.1002/ajmg.1320580316. [DOI] [PubMed] [Google Scholar]
  • 49.Leonard H, Bower C, English D. The prevalence and incidence of Rett Syndrome in Australia. Eur Child Adolesc Psychiatry. 1997;6:1–3. [PubMed] [Google Scholar]
  • 50.Leonard H, Glasson EJ, Thomson M, et al. Metacarpophalangeal pattern profile and bone age in Rett syndrome: Further radiological clues to the diagnosis. Am J Med Genet. 1999;83:88–95. doi: 10.1002/(sici)1096-8628(19990312)83:2<88::aid-ajmg3>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  • 51.Ellaway CJ, Williams K, Leonard H, Higgins G, Wilcken B, Christodoulou J. Rett Syndrome: Randomised controlled trial of L-carnitine. J Child Neurol. 1999;14:162–7. doi: 10.1177/088307389901400306. [DOI] [PubMed] [Google Scholar]
  • 52.Royle J, Williams K, Elliott E, et al. Kawasaki disease in Australia 1993–5. Arch Dis Child. 1998;78:33–9. doi: 10.1136/adc.78.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Wilken B, Wiley V. Newborn screening for congenital adrenal hyperplasia: Testing to commence in New South Wales. J Paediatr Child Health. 1996;32:76. [PubMed] [Google Scholar]
  • 54.Forrest JM, Mego S, Burgess MA. Congenital varicella in Australia. J Paediatr Child Health. 2000;36:108–13. doi: 10.1046/j.1440-1754.2000.00474.x. [DOI] [PubMed] [Google Scholar]

Articles from Paediatrics & Child Health are provided here courtesy of Oxford University Press

RESOURCES